Brain metastases: pathobiology and emerging targeted therapies
- 3 January 2012
- journal article
- review article
- Published by Springer Nature in Acta Neuropathologica
- Vol. 123 (2) , 205-222
Abstract
Brain metastases (BM) are common in cancer patients and are associated with high morbidity and poor prognosis, even after intensive multimodal therapy including resection, radiotherapy (stereotactic radiosurgery or whole brain radiotherapy) and chemotherapy. However, advances in the understanding of the pathobiology of BM and the development of molecular targeted agents hold promise for improved prophylaxis and therapy of BM. Here we provide a comprehensive review of the current concepts on mechanisms of the brain-metastatic cascade involving hematogenous dissemination of tumor cells, attachment to microvessel endothelial cells, extravasation into the brain, interaction with the local microenvironment, angiogenesis and intraparenchymal proliferation. Transendothelial migration depends on adhesion molecules such as integrins, selectins and chemokines. Tumor cells invade the brain by degrading extracellular matrix components using heparanase and matrix metalloproteinases. Astrocytes and microglial cells exert not only anti-, but also pro-neoplastic effects on brain-invading tumor cells. Some tumor types (e.g. melanoma) show prominent cooption of preexisting vasculature, while other tumor types (e.g. lung cancer) tend to show early angiogenesis after brain invasion. In this article we also critically summarize the data on currently studied targeted therapeutics in BM especially in the context of recent preclinical data. The most promising agents for BM patients include anti-angiogenic drugs, inhibitors of v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) for BRAF V600E mutated melanoma and inhibitors of epithelial growth factor receptor for non-small cell lung cancer. Molecular analysis of the BRAF V600E status of melanoma BM using DNA-based methods or immunohistochemistry may soon enter the routine neuropathological practice.Keywords
This publication has 142 references indexed in Scilit:
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast CancerPharmaceutical Research, 2011
- Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brainClinical & Experimental Metastasis, 2011
- Modulation of GEF‐H1 Induced Signaling by Heparanase in Brain Metastatic Melanoma CellsJournal of Cellular Biochemistry, 2010
- Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancerJournal of Neuro-Oncology, 2010
- Vascular gene expression patterns are conserved in primary and metastatic brain tumorsJournal of Neuro-Oncology, 2010
- The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guidelineJournal of Neuro-Oncology, 2009
- The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topicsJournal of Neuro-Oncology, 2009
- WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma MetastasisCell, 2009
- Breast Cancer Metastasis to the Central Nervous SystemThe American Journal of Pathology, 2005
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997